Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis.

M Kulozik1, A Hogg, B Lankat-Buttgereit

  • 1Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Federal Republic of Germany.

The Journal of Clinical Investigation
|September 1, 1990

Related Experiment Videos

View abstract on PubMed

Summary
This summary is machine-generated.

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Co-localization Of Transforming Growth Factor Beta 2 With Alpha 1(i) Procollagen Mrna In Tissue Sections Of Patients With Systemic Sclerosis.

    • Transforming growth factor beta 2 (TGF-beta 2) mRNA is present around dermal blood vessels in active systemic sclerosis (SSc) but not in fibrotic SSc or controls. This suggests TGF-beta 2 may drive SSc fibrosis.

    Area of Science:

    • Immunodermatology
    • Molecular Biology
    • Connective Tissue Diseases

    Background:

    • Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis.
    • The molecular mechanisms underlying SSc pathogenesis, particularly fibrosis, require further elucidation.
    • Transforming growth factor beta (TGF-beta) signaling is implicated in fibrotic processes.

    Purpose of the Study:

    • To investigate the role of transforming growth factor beta 2 (TGF-beta 2) in the pathogenesis of SSc.
    • To determine the spatial and temporal expression of TGF-beta 2 mRNA in SSc skin biopsies.

    Main Methods:

    • In situ hybridization was performed on skin biopsies.
    • Samples were obtained from six SSc patients (inflammatory and fibrotic stages).
    • Control groups included patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), and healthy individuals.

    Main Results:

    • TGF-beta 2 mRNA was co-localized with pro alpha 1(I) collagen mRNA around dermal blood vessels in the inflammatory stage of SSc.
    • No TGF-beta 2 or collagen expression was detected in the fibrotic stage of SSc.
    • Gene expression was absent in SLE patients and healthy controls.

    Conclusions:

    • TGF-beta 2 expression around dermal blood vessels correlates with active fibrosis in SSc.
    • Inflammatory cells may release TGF-beta 2, contributing to collagen gene dysregulation.
    • TGF-beta 2 is a potential mediator in the development of SSc-associated fibrosis.

    Related Experiment Videos